Compare · FREQ vs JNJ
FREQ vs JNJ
Side-by-side comparison of Frequency Therapeutics Inc. (FREQ) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FREQ and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $547.28B, about 3125.8x FREQ ($175.1M).
- JNJ has hit the wire 28 times in the past 4 weeks while FREQ has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 3 for FREQ).
- Company
- Frequency Therapeutics Inc.
- Johnson & Johnson
- Price
- $15.00+5204.10%
- $229.94+1.15%
- Market cap
- $175.1M
- $547.28B
- 1M return
- -
- -5.89%
- 1Y return
- -
- +47.14%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 0
- 28
- Recent ratings
- 3
- 25
Frequency Therapeutics Inc.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest FREQ
- NorthStar Appoints Peter Pfreundschuh to Board of Managers
- SEC Form SC 13G/A filed by Frequency Therapeutics Inc. (Amendment)
- SEC Form SC 13G/A filed by Frequency Therapeutics Inc. (Amendment)
- SEC Form SC 13G filed by Frequency Therapeutics Inc.
- SEC Form SC 13G filed by Frequency Therapeutics Inc.
- SEC Form 424B3 filed by Frequency Therapeutics Inc.
- Frequency Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form EFFECT filed by Frequency Therapeutics Inc.
- SEC Form 424B3 filed by Frequency Therapeutics Inc.
- SEC Form S-1/A filed by Frequency Therapeutics Inc. (Amendment)
Latest JNJ
- Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
- Johnson & Johnson filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director West Nadja
- SEC Form 4 filed by Director Weinberger Mark A
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Morikis John G
- SEC Form 4 filed by Director Mcclellan Mark B.
- SEC Form 4 filed by Director Joly Hubert
- SEC Form 4 filed by Director Johnson Paula A